See every side of every news story
Published loading...Updated

Altimmune Expands Weight-Loss Drug Pemvidutide's Potential To Alcohol-Related Disorders - Altimmune (NASDAQ:ALT)

Summary by Benzinga
Altimmune Inc (NASDAQ:ALT) hosted a virtual R&D day on Thursday, marking the first disclosure of Alcohol Use Disorder (AUD) and Alcohol Liver Disease (ALD) as potential developments for pemvidutide. Phase 2 trials for pemvidutide in AUD and ALD are expected to start in the second and third quarters of 2025, respectively. Altimmune anticipates pemvidutide will reduce alcohol cravings, improve liver health and promote weight loss. Also Read: Novo …

3 Articles

All
Left
Center
2
Right
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 100% of the sources are Center
100% Center
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Medscape broke the news in United States on Friday, March 14, 2025.
Sources are mostly out of (0)

Similar News Topics

You have read out of your 5 free daily articles.

Join us as a member to unlock exclusive access to diverse content.